Table 2.
AEs in greater than or equal to 20% of CLL and RT cohorts, listed in order of frequency
| AE (CLL cohort, N = 46) | All grades |
Grade 1 |
Grade 2 |
Grade 3 |
Grade 4 |
|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| Infusion reaction | 38 (83) | 3 (6.5) | 31 (67) | 4 (8.7) | — |
| Neutropenia | 27 (59) | 4 (8.7) | 7 (15) | 10 (22) | 6 (13) |
| Leukopenia | 26 (57) | 7 (15) | 10 (22) | 8 (17) | 1 (2.2) |
| Diarrhea | 23 (50) | 13 (28) | 5 (11) | 5 (11) | — |
| Infection∗ | 23 (50)∗ | 2 (4.3) | 14 (30) | 6 (13) | — |
| Nausea | 21 (46) | 16 (35) | 5 (11) | — | — |
| Lymphopenia | 20 (43) | 4 (8.7) | 9 (20) | 6 (13) | 1 (2.2) |
| Thrombocytopenia | 20 (43) | 15 (33) | 4 (9) | — | 1 (2.2) |
| Anemia | 18 (39) | 13 (28) | 2 (4) | 3 (7) | — |
| Creatinine increase | 18 (39) | 17 (37) | 1 (2) | — | — |
| Fatigue | 13 (28) | 10 (22) | 3 (6) | ||
| AST increase | 13 (28) | 9 (20) | 2 (4) | 2 (4) | — |
| ALT increase | 11 (24) | 5 (11) | 4 (9) | 2 (4) | — |
| Alkaline phosphate increase | 10 (22) | 9 (20) | 1 (2) | — | |
| Hypocalcemia | 10 (22) | 7 (15) | 3 (7) | ||
| Headache | 10 (22) | 7 (15) | 3 (7) | ||
| Chills | 9 (20) | 9 (20) | — | ||
| Hyperkalemia | 9 (20) | 8 (17) | 1 (2) | ||
| Richter cohort (N = 5) | |||||
| Diarrhea | 3 (60%) | 1 (20%) | |||
| Fatigue | 3 (60%) | 2 (40%) | |||
| Nausea | 3 (60%) | 2 (40%) | |||
| Infusion reaction | 2 (40%) | 1 (20%) | 1 (20%) | ||
| Infection∗ | 2 (40%) | 1 (20%) | 1 (20%) | ||
| Headache | 2 (40%) | 1 (20%) | |||
| Abdominal pain | 2 (40%) | 1 (20%) | |||
| Decreased appetite | 2 (40%) | 1 (20%) | |||
| Neutropenia | 1 (20%) | ||||
| Hypotension | 1 (20%) | ||||
| Rash maculopapular | 1 (20%) | ||||
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
∗
There was 1 case of grade 5 infection owing to COVID in CLL cohort and 1 case of grade 3/4 COVID-1 in the Richter cohort.